OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 332.97 Million TWD | -57.35% |
| 2022 | 780.64 Million TWD | 6.1% |
| 2021 | 735.73 Million TWD | 140.98% |
| 2020 | 305.31 Million TWD | -42.84% |
| 2019 | 534.12 Million TWD | 106.41% |
| 2018 | 258.76 Million TWD | -32.95% |
| 2017 | 385.95 Million TWD | 32.63% |
| 2016 | 291 Million TWD | 0.67% |
| 2015 | 289.05 Million TWD | -37.57% |
| 2014 | 462.99 Million TWD | -19.35% |
| 2013 | 574.08 Million TWD | 434.92% |
| 2012 | 107.32 Million TWD | 138.48% |
| 2011 | 45 Million TWD | 123.28% |
| 2010 | 20.15 Million TWD | -59.73% |
| 2009 | 50.05 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 272.15 Million TWD | -18.27% |
| 2024 Q2 | 540.29 Million TWD | 98.52% |
| 2023 Q4 | 332.97 Million TWD | -14.81% |
| 2023 Q2 | 437.27 Million TWD | -11.91% |
| 2023 Q3 | 390.87 Million TWD | -10.61% |
| 2023 FY | 332.97 Million TWD | -57.35% |
| 2023 Q1 | 496.39 Million TWD | -36.41% |
| 2022 Q4 | 780.64 Million TWD | -9.74% |
| 2022 FY | 780.64 Million TWD | 6.1% |
| 2022 Q1 | 678.17 Million TWD | -7.82% |
| 2022 Q2 | 740.34 Million TWD | 9.17% |
| 2022 Q3 | 864.88 Million TWD | 16.82% |
| 2021 Q3 | 647.52 Million TWD | 29.94% |
| 2021 Q4 | 735.73 Million TWD | 13.62% |
| 2021 FY | 735.73 Million TWD | 140.98% |
| 2021 Q1 | 302.06 Million TWD | -1.06% |
| 2021 Q2 | 498.33 Million TWD | 64.97% |
| 2020 Q3 | 497.8 Million TWD | -10.86% |
| 2020 Q2 | 558.45 Million TWD | -6.94% |
| 2020 Q4 | 305.31 Million TWD | -38.67% |
| 2020 Q1 | 600.12 Million TWD | 12.36% |
| 2020 FY | 305.31 Million TWD | -42.84% |
| 2019 Q3 | 501.39 Million TWD | 94.32% |
| 2019 Q4 | 534.12 Million TWD | 6.53% |
| 2019 Q1 | 264.95 Million TWD | 2.39% |
| 2019 Q2 | 258.02 Million TWD | -2.62% |
| 2019 FY | 534.12 Million TWD | 106.41% |
| 2018 Q2 | 291.67 Million TWD | -23.55% |
| 2018 FY | 258.76 Million TWD | -32.95% |
| 2018 Q1 | 381.52 Million TWD | -1.15% |
| 2018 Q4 | 258.76 Million TWD | -0.76% |
| 2018 Q3 | 260.74 Million TWD | -10.6% |
| 2017 FY | 385.95 Million TWD | 32.63% |
| 2017 Q4 | 385.95 Million TWD | 17.07% |
| 2017 Q3 | 329.66 Million TWD | -15.23% |
| 2017 Q2 | 388.89 Million TWD | 20.45% |
| 2017 Q1 | 322.86 Million TWD | 10.95% |
| 2016 Q4 | 291 Million TWD | 0.0% |
| 2016 Q1 | - TWD | -100.0% |
| 2016 FY | 291 Million TWD | 0.67% |
| 2016 Q2 | 299.53 Million TWD | 0.0% |
| 2015 Q1 | 339.62 Million TWD | -26.65% |
| 2015 Q3 | 306.1 Million TWD | -5.36% |
| 2015 Q2 | 323.44 Million TWD | -4.76% |
| 2015 FY | 289.05 Million TWD | -37.57% |
| 2015 Q4 | 289.05 Million TWD | -5.57% |
| 2014 Q1 | 554.83 Million TWD | -3.35% |
| 2014 FY | 462.99 Million TWD | -19.35% |
| 2014 Q4 | 462.99 Million TWD | -3.28% |
| 2014 Q3 | 478.7 Million TWD | -11.45% |
| 2014 Q2 | 540.61 Million TWD | -2.56% |
| 2013 Q1 | 457.06 Million TWD | 325.89% |
| 2013 Q2 | 466.16 Million TWD | 1.99% |
| 2013 FY | 574.08 Million TWD | 434.92% |
| 2013 Q4 | 574.08 Million TWD | -1.02% |
| 2013 Q3 | 580.01 Million TWD | 24.42% |
| 2012 Q4 | 107.32 Million TWD | 0.0% |
| 2012 Q2 | 66.46 Million TWD | 0.0% |
| 2012 Q3 | - TWD | -100.0% |
| 2012 FY | 107.32 Million TWD | 138.48% |
| 2011 FY | 45 Million TWD | 123.28% |
| 2011 Q2 | 20.12 Million TWD | 0.0% |
| 2011 Q4 | 45 Million TWD | 0.0% |
| 2010 FY | 20.15 Million TWD | -59.73% |
| 2010 Q4 | 20.15 Million TWD | 0.0% |
| 2009 FY | 50.05 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 1.44 Billion TWD | 76.932% |
| Apex Medical Corp. | 364.55 Million TWD | 8.662% |
| Applied BioCode Corporation | 34.43 Million TWD | -867.079% |